{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Edesa Biotech, Inc."},"Symbol":{"label":"Symbol","value":"EDSA"},"Address":{"label":"Address","value":"100 SPY COURT, MARKHAM, Ontario, L3R 5H6, Canada"},"Phone":{"label":"Phone","value":"+1 905 475-1234"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side-effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients."},"CompanyUrl":{"label":"Company Url","value":"https://www.edesabiotech.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Blair Gordon","title":"Vice President-Research & Development"},{"name":"Pardeep Nijhawan","title":"Chief Executive Officer, Secretary & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}